Matches in Nanopublications for { ?s ?p "[Monitored noninvasively through radioiodine-based single-photon emission computed tomography/computed tomography, intratumorally virus-delivered NIS has concentrated the radioiodine in the MV-NIS-treated tumors in the FaDu mouse xenograft model of human SCCHN, and the antitumor effect could be boosted significantly (p<0.05) either with concomitant cyclophosphamide therapy or with appropriately timed administration of radioiodine (131)I. MV-NIS could be a promising new anticancer agent that may substantially enhance the outcomes of standard therapy after intratumoral administration in patients with locally advanced SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP697850.RAeOTSDos7iG6f2I9cTF9m_ciiJx2WD-0DuRS4UJLeVqA130_assertion description "[Monitored noninvasively through radioiodine-based single-photon emission computed tomography/computed tomography, intratumorally virus-delivered NIS has concentrated the radioiodine in the MV-NIS-treated tumors in the FaDu mouse xenograft model of human SCCHN, and the antitumor effect could be boosted significantly (p<0.05) either with concomitant cyclophosphamide therapy or with appropriately timed administration of radioiodine (131)I. MV-NIS could be a promising new anticancer agent that may substantially enhance the outcomes of standard therapy after intratumoral administration in patients with locally advanced SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697850.RAeOTSDos7iG6f2I9cTF9m_ciiJx2WD-0DuRS4UJLeVqA130_provenance.
- NP952401.RAnF69Ic_xk8ZTAP_56oisZeD3cn-pGgpKnT6sJdP_jGs130_assertion description "[Monitored noninvasively through radioiodine-based single-photon emission computed tomography/computed tomography, intratumorally virus-delivered NIS has concentrated the radioiodine in the MV-NIS-treated tumors in the FaDu mouse xenograft model of human SCCHN, and the antitumor effect could be boosted significantly (p<0.05) either with concomitant cyclophosphamide therapy or with appropriately timed administration of radioiodine (131)I. MV-NIS could be a promising new anticancer agent that may substantially enhance the outcomes of standard therapy after intratumoral administration in patients with locally advanced SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP952401.RAnF69Ic_xk8ZTAP_56oisZeD3cn-pGgpKnT6sJdP_jGs130_provenance.